These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 29325642)

  • 1. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.
    Tsimikas S; Fazio S; Ferdinand KC; Ginsberg HN; Koschinsky ML; Marcovina SM; Moriarty PM; Rader DJ; Remaley AT; Reyes-Soffer G; Santos RD; Thanassoulis G; Witztum JL; Danthi S; Olive M; Liu L
    J Am Coll Cardiol; 2018 Jan; 71(2):177-192. PubMed ID: 29325642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
    Hung MY; Tsimikas S
    Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Frontiers in Lp(a)-Targeted Therapies.
    Borrelli MJ; Youssef A; Boffa MB; Koschinsky ML
    Trends Pharmacol Sci; 2019 Mar; 40(3):212-225. PubMed ID: 30732864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.
    Scipione CA; Koschinsky ML; Boffa MB
    Crit Rev Clin Lab Sci; 2018 Jan; 55(1):33-54. PubMed ID: 29262744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma lipoprotein(a) concentration as an independent predictor of hemodynamic progression of aortic valve stenosis.
    Tomova VD; Alexandrova ML; Atanasova MA; Tzekova ML; Rashev TR; Ahmad S
    Mol Cell Biochem; 2020 Sep; 472(1-2):199-207. PubMed ID: 32577944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future role of lipoprotein(a) in preventive cardiology.
    Berman AN; Blankstein R
    Curr Opin Cardiol; 2019 Sep; 34(5):514-518. PubMed ID: 31261178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a) and calcific aortic valve stenosis: A systematic review.
    Guddeti RR; Patil S; Ahmed A; Sharma A; Aboeata A; Lavie CJ; Alla VM
    Prog Cardiovasc Dis; 2020; 63(4):496-502. PubMed ID: 32526213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.
    Boffa MB; Koschinsky ML
    Nat Rev Cardiol; 2019 May; 16(5):305-318. PubMed ID: 30675027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Tsimikas S; Stroes ESG
    Atherosclerosis; 2020 May; 300():1-9. PubMed ID: 32234580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current landscape of lipoprotein(a) in calcific aortic valvular disease.
    Hsieh G; Rizk T; Berman AN; Biery DW; Blankstein R
    Curr Opin Cardiol; 2021 Sep; 36(5):542-548. PubMed ID: 34397461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathobiology of Lp(a) in calcific aortic valve disease.
    Mathieu P; Arsenault BJ; Boulanger MC; Bossé Y; Koschinsky ML
    Expert Rev Cardiovasc Ther; 2017 Oct; 15(10):797-807. PubMed ID: 28816078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
    Yeang C; Cotter B; Tsimikas S
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a).
    Wilson DP; Koschinsky ML; Moriarty PM
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):159-173. PubMed ID: 33534258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions.
    Marcovina SM; Koschinsky ML; Albers JJ; Skarlatos S
    Clin Chem; 2003 Nov; 49(11):1785-96. PubMed ID: 14578310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a) in clinical practice: A guide for the clinician.
    Krittanawong C; Maitra NS; El-Sherbini AH; Shah N; Lavie CJ; Shapiro MD; Virani SS
    Prog Cardiovasc Dis; 2023; 79():28-36. PubMed ID: 37516261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Vuorio A; Watts GF; Kovanen PT
    Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective.
    Arsenault BJ; Kamstrup PR
    Atherosclerosis; 2022 May; 349():7-16. PubMed ID: 35606078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a)-60 Years Later-What Do We Know?
    Pasławska A; Tomasik PJ
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
    Tsimikas S
    J Am Coll Cardiol; 2017 Feb; 69(6):692-711. PubMed ID: 28183512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Lipoprotein(a) Electrophoretic and Immunoassay Methods in Discriminating Risk of Calcific Aortic Valve Disease and Incident Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis.
    Cao J; Steffen BT; Guan W; Budoff M; Michos ED; Kizer JR; Post WS; Tsai MY
    Clin Chem; 2017 Nov; 63(11):1705-1713. PubMed ID: 28904058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.